Biomerica Inc.
1533 Monrovia Avenue
Newport Beach
California
92663
United States
Tel: 714-645-2111-or-800-854-3002
Fax: 714-722-6674
Website: http://www.biomerica.com/
Email: bmra@biomerica.com
139 articles about Biomerica Inc.
-
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
1/10/2023
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board.
-
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAEExpands Commercialization Efforts in Areas with High Unmet Needs
12/8/2022
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device.
-
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
11/2/2022
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting.
-
Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores
10/14/2022
Biomerica, Inc. announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores.
-
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
10/13/2022
Biomerica, Inc., a global provider of advanced medical products, reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase.
-
Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
9/29/2022
Biomerica, Inc. announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amazon and fulfilled by Amazon.
-
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
8/30/2022
Biomerica, Inc. announced plans to launch its InFoods® IBS test before calendar year end.
-
Biomerica Reports Fiscal 2022 Year End Results
8/29/2022
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results.
-
Biomerica to Participate at BTIG Biotech Conference
6/23/2022
Biomerica Inc. (NASDAQ: BMRA ) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th , 2022.
-
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
5/12/2022
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, announces CE Mark for its hp+detect™ diagnostic test that detects Helicobacter pylori (H. pylori) bacteria.
-
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
4/26/2022
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for hp+detect™, a new product that detects the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population.
-
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
4/14/2022
Biomerica, Inc. today announced its fiscal third quarter and nine month results ended February 28, 2022.
-
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
2/8/2022
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced positive topline results from the endpoint clinical trial of its InFoods® IBS diagnostic-guided therapy.
-
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
1/13/2022
Net sales for the three months ended November 30, 2021 were $4.6 million as compared to net sales of $1.4 million for the same three months in fiscal 2021, an increase of $3.2 million, or 239%.
-
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
12/16/2021
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021.
-
Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening
11/19/2021
Biomerica Inc. (NASDAQ: BMRA) today announced that Dr. Brooks Cash, one the nation’s most recognized leaders in Gastroenterology medicine, has agreed to chair Biomerica’s newly formed Colorectal Cancer Scientific Advisory Board (“SAB”).
-
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
11/4/2021
Biomerica, Inc. announced that the Canadian Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome.
-
Biomerica Launches New Website for Its Aware® Breast Exam Device
10/29/2021
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women.
-
Biomerica Reports Results for Fiscal First Quarter ended August 31, 2021
10/15/2021
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its first quarter fiscal 2022 financial results.
-
Biomerica Reports Fiscal 2021 Year End Results
8/28/2021
Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2021 financial results.